{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:20:47Z","timestamp":1769271647677,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Parasitology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.exppara.2012.05.007","type":"journal-article","created":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T13:36:24Z","timestamp":1337693784000},"page":"377-382","source":"Crossref","is-referenced-by-count":25,"title":["Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis"],"prefix":"10.1016","volume":"131","author":[{"given":"Nishi","family":"Shakya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shraddha A.","family":"Sane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeti","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exppara.2012.05.007_b0005","first-page":"285736","article-title":"Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2","volume":"30","author":"Aliprantis","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.exppara.2012.05.007_b0010","first-page":"1847","article-title":"Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, immunomodulator","volume":"33","author":"Arevalo","year":"2001","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.exppara.2012.05.007_b0015","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1128\/AAC.00524-10","article-title":"Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental Visceral Leishmaniasis throughTh1-biased immunomodulation","volume":"55","author":"Banerjee","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2012.05.007_b0020","first-page":"489","article-title":"Anti-IL-10 mAb protection against experimental Visceral Leishmaniasis via induction of Th1 cytokines and nitric oxide","volume":"47","author":"Bhattacharjee","year":"2009","journal-title":"Indian J. Exp. Biol."},{"key":"10.1016\/j.exppara.2012.05.007_b0030","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1462-5822.2008.01146.x","article-title":"Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example","volume":"10","author":"Bogdon","year":"2008","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.exppara.2012.05.007_b0035","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1074\/jbc.M109.036343","article-title":"TLR2 activation is essential to induce a th1 shift in human PBMCs by plant stanols and plant sterols","volume":"285","author":"Br\u00fcll","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.exppara.2012.05.007_b0040","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1086\/314782","article-title":"Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action","volume":"179","author":"Buates","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.exppara.2012.05.007_b0045","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1039\/b908664c","article-title":"Immunotherapy for cancer: synthetic carbohydrate-based vaccines","volume":"28","author":"Buskas","year":"2009","journal-title":"Chem. Commun."},{"key":"10.1016\/j.exppara.2012.05.007_b0050","doi-asserted-by":"crossref","first-page":"113R","DOI":"10.1093\/glycob\/cwj125","article-title":"Glycopeptides as versatile tools for glycobiology","volume":"16","author":"Buskas","year":"2006","journal-title":"Glycobiology"},{"key":"10.1016\/j.exppara.2012.05.007_b0055","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0002-9440(10)64005-9","article-title":"A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells","volume":"158","author":"De Larco","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.exppara.2012.05.007_b0060","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1128\/IAI.00088-06","article-title":"Gamma interferon secretion by human V\u03b32V\u03b42 T cells after stimulation with antibody against the T-cell receptor plus the toll-like receptor 2 agonist Pam3Cys","volume":"74","author":"Deetz","year":"2006","journal-title":"Infect. Immun."},{"key":"10.1016\/j.exppara.2012.05.007_b0065","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/14728210903153862","article-title":"Developments in the treatment of Visceral Leishmaniasis","volume":"14","author":"den Boer","year":"2009","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.exppara.2012.05.007_b0070","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-3083.2007.02025.x","article-title":"Induction of host protective Th1 immune response by chemokines of Leishmania donovani infected BALB\/c mice","volume":"66","author":"Dey","year":"2007","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.exppara.2012.05.007_b0075","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.actatropica.2004.11.009","article-title":"Efficacy of picroliv combination with miltefosine, an orally effective antileishmanial drug against experimental Visceral Leishmaniasis","volume":"94","author":"Gupta","year":"2005","journal-title":"Acta Trop."},{"issue":"11","key":"10.1016\/j.exppara.2012.05.007_b0080","doi-asserted-by":"crossref","first-page":"e871","DOI":"10.1371\/journal.pntd.0000871","article-title":"CD8 Cells of patients with diffuse Cutaneous Leishmaniasis display functional exhaustion: the latter is reversed, in vitro, by TLR2 agonists","volume":"4","author":"Herna\u00b4ndez-Ruiz","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.exppara.2012.05.007_b0085","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1021\/jo015521z","article-title":"Solution and solid-support synthesis of a potential leishmaniasis carbohydrate vaccine","volume":"66","author":"Hewitt","year":"2001","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.exppara.2012.05.007_b0090","doi-asserted-by":"crossref","first-page":"6715","DOI":"10.4049\/jimmunol.178.11.6715","article-title":"Cutting edge: TLR2 directly triggers Th1 effect or functions","volume":"178","author":"Imanishi","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.exppara.2012.05.007_b0100","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/infdis\/157.5.973","article-title":"Immunotherapy for intracellular L. donovani infection: gamma interferon plus pentavalent antimony","volume":"157","author":"Murray","year":"1988","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.exppara.2012.05.007_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trstmh.2009.07.026","article-title":"Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration","volume":"104","author":"Musa","year":"2010","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.exppara.2012.05.007_b0110","first-page":"937","article-title":"Immunomodulatory activity of analog of muramyl dipeptide and their use as adjunct to chemotherapy of Leishmania donovani in hamster","volume":"5","author":"Puri","year":"2005","journal-title":"Int. Immunol. pharmacol."},{"issue":"6","key":"10.1016\/j.exppara.2012.05.007_b0115","doi-asserted-by":"crossref","first-page":"e11216","DOI":"10.1371\/journal.pone.0011216","article-title":"Linear and branched glyco-lipopeptidevaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity","volume":"5","author":"Renaudet","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.exppara.2012.05.007_b0120","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/jac\/dkq164","article-title":"CpGoligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental Visceral Leishmaniasis","volume":"65","author":"Sane","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.exppara.2012.05.007_b0130","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1189\/jlb.0903415","article-title":"Ascorbate-mediated enhancement of reactive oxygen species generation from polymorphonuclear leukocyte: modulatory effect of nitric oxide","volume":"75","author":"Sharma","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.exppara.2012.05.007_b0135","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.actatropica.2011.05.017","article-title":"Improved treatment of Visceral Leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator\u2014Picroliv","volume":"119","author":"Shakya","year":"2011","journal-title":"Acta Trop."},{"key":"10.1016\/j.exppara.2012.05.007_b0140","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4049\/jimmunol.170.1.194","article-title":"Toll-like receptor 2 ligands as adjuvants for human Th1 responses","volume":"170","author":"Sieling","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.exppara.2012.05.007_b0145","first-page":"431","article-title":"Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations","volume":"286","author":"Tarpey","year":"2004","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.exppara.2012.05.007_b0150","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1574-695X.2007.00311.x","article-title":"Immuneresponse to leishmania: paradox rather than paradigm","volume":"51","author":"Tripathi","year":"2007","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.exppara.2012.05.007_b0155","first-page":"103","article-title":"Flow cytometry study of polymorphonuclear neutrophil oxidative burst: a comparison of three fluorescent probes","volume":"331","author":"Walrand","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.exppara.2012.05.007_b0160","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1128\/AAC.46.3.929-931.2002","article-title":"In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii","volume":"46","author":"Yardley","year":"2002","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Experimental Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014489412001683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014489412001683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T09:21:38Z","timestamp":1542964898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014489412001683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0014489412001683"],"URL":"https:\/\/doi.org\/10.1016\/j.exppara.2012.05.007","relation":{},"ISSN":["0014-4894"],"issn-type":[{"value":"0014-4894","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}